Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
5 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Yesterday
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

Peri-traumatic nausea predicts PTSD symptom development

01 Dec 2018
Mind training is the key to prevent PTSD among emergency responders handling trauma cases

Peri-traumatic nausea correlates with a prospective risk of post-traumatic stress disorder (PTSD) symptom development, a study has shown.

“Further studies are needed to determine the mechanistic role of nausea as an intermediate phenotype of PTSD risk,” the investigators said.

Participants were recruited from the following locations: the emergency departments (ED) at Grady Memorial Hospital (GMH; n=363), from multiple other ED sites in the TRYUMPH Research Network (n=1,846) and from the ED during evaluation for suspected acute coronary syndrome in the REACH cohort (n=758).

The investigators used the administration of IV ondansetron, the most predominantly used antiemetic at GMH, as a surrogate marker for nausea in the initial GMH cohort. Then, they directly evaluated nausea in the internal validation at GMH and within the replication TRYUMPH Research Network and REACH cohorts.

In adjusted models, an association was observed between ondansetron administration and increased 1- and 3-month PTSD symptoms in the GMH cohort (p<0.05 for all). Nausea was a significant predictor of 1- (n=68; p=0.009) and 3-month (n=54; p=0.029) PTSD symptoms in the GMH internal validation.

In the TRYUMPH cohort, nausea significantly correlated with increased PTSD symptoms in adjusted models (p=0.009), while peri-traumatic nausea in the REACH cohort correlated with PTSH symptom severity at the 1-month follow-up in adjusted models (p≤0.008).

“While nausea often develops following exposure to trauma, little is known regarding the relationship between peri-traumatic nausea and prospective risk for developing PTSD,” the investigators noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
5 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Yesterday
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.